Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.70 +6.96 (+0.13%) Dow
38,884.26 +31.99 (+0.08%) Nasdaq
16,332.56 -16.69 (-0.10%) Bitcoin USD
62,320.04 -1,196.19 (-1.88%) CMC Crypto 200
1,319.69 +25.02 (+1.93%)
Psyence Group Inc. (PSYGF)
| Previous close | 0.0177 |
| Open | 0.0146 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.0146 - 0.0148 |
| 52-week range | 0.0127 - 0.2200 |
| Volume | |
| Avg. volume | 16,147 |
| Market cap | 2.027M |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that its Australian subsidiary, Psyence Australia Pty Ltd ("Psyence Australia"), has entered into a partnership with Fluence, a global leader in profess
- GlobeNewswire
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
TORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- Further to the announcement by Psyence Group Inc ("Psyence" or the "Company") (CSE:PSYG) of its plans for the strategic restructuring of its non-clinical business through a conditional M&A transaction (the "Transaction"), Psyence is pleased to announce that the conditions to implement the Transaction have been met and that the Transaction has closed. Psyence has built a network of potential clients and customers, and successfully and lawfully distribut
- GlobeNewswire
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ listed associate, Psyence Biomedical Ltd (NASDAQ:PBM) ("PBM" or "Psyence Biomed") has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia. T
